Stage IV Pancreatic Cancer Clinical Trial
Official title:
VXM01 Phase I Dose Escalation Study in Patients With Locally Advanced, Inoperable and Stage IV Pancreatic Cancer to Examine Safety, Tolerability, and Immune Response to the Investigational VEGFR-2 DNA Vaccine VXM01
Verified date | June 2015 |
Source | Vaximm GmbH |
Contact | n/a |
Is FDA regulated | No |
Health authority | Germany: Paul-Ehrlich-Institut |
Study type | Interventional |
First-in-human phase I dose escalation study in patients with locally advanced, inoperable and stage IV pancreatic cancer to examine safety, tolerability, and immune response to the investigational VEGFR-2 DNA vaccine VXM01 to examine safety and tolerability, clinical and immunogenic response to the investigational vascular endothelial growth factor receptor 2 (VEGFR-2) DNA vaccine VXM01, and to define the maximum tolerated dose.
Status | Completed |
Enrollment | 72 |
Est. completion date | December 2014 |
Est. primary completion date | October 2014 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Written informed consent, signed and dated - Locally advanced, inoperable and stage IV pancreatic cancer patients according to UICC based on diagnostic imaging using computer-tomography (CT) or histological examinations - Male or post-menopausal female - Age above or equal to 18 years - Chemotherapy naïve within 60 days before screening visit except gemcitabine treatment - Karnovsky index >70 - Life expectancy >3 months - Adequate renal, hepatic, and bone marrow function - Absolute neutrophil count >1500/µL - Hemoglobin >10 g/dL - Platelets >75000/µL - Prothrombin time and international normalized ratio (INR) <1.5 times upper limit of normal (ULN) (except under anticoagulant treatment) - Aspartate aminotransferase <4 times ULN - Alanine aminotransferase <4 times ULN - Total bilirubin <3 times ULN - Creatinine clearance estimated according to Cockcroft-Gault >30 mL/min - Proteinuria <1 g protein on 24 h urine collection Exclusion Criteria: - State after pancreas resection (complete or partial) - Resectable disease - Drug trial participation within 60 days before screening visit - Other previous or current malignancy except basal or squamous cell skin cancer, in situ cervical cancer, or any other cancer from which the patient has been disease-free for <2 years - Prior vaccination with Ty21a - Cardiovascular disease defined as: - Uncontrolled hypertension (systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg) - Arterial thromboembolic event within 6 months before randomization including: - Myocardial infarction - Unstable angina pectoris - Cerebrovascular accident - Transient ischemic attack - Congestive heart failure New York Heart Association grade III to IV - Serious ventricular arrhythmia requiring medication - Clinically significant peripheral artery disease > grade 2b according to Fontaine - Hemoptysis within 6 months before randomization - Esophageal varices - Upper or lower gastrointestinal bleeding within 6 months before randomization - Significant traumatic injury within 4 weeks before randomization - Non-healing wound, bone fracture or any history of gastrointestinal ulcers within three years before inclusion, or positive gastroscopy within 3 months before inclusion - Gastrointestinal fistula - Thrombolysis therapy within 4 weeks before randomization - Bowel obstruction within the last 30 days before screening visit - Liver cirrhosis = grade B according to Child-Pugh Score-Classification - Presence of any acute or chronic systemic infection - Radiotherapy within 4 weeks before randomization - Major surgical procedures, or open biopsy within 4 weeks before randomization - Fine needle aspiration within 7 days before randomization - Chronic concurrent therapy within 2 weeks before and during the double-blind study period with: - Corticosteroids (except steroids for adrenal failure) or immunosuppressive agents - Antibiotics - Bevacizumab - Any epidermal growth factor receptor inhibitor - Chemotherapy except gemcitabine before Day 10 - Multi-drug resistant gram-negative germ - Pregnancy - Lactation - Inability to comply with study and/or follow-up procedures - History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that might affect the interpretation of the study results or render the patient at high risk for treatment complications - Women of childbearing potential - Any history of drug hypersensitivity - Any condition which results in an undue risk for the patient during the study participation according to the investigator |
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Germany | Clinic of General Surgery | Heidelberg |
Lead Sponsor | Collaborator |
---|---|
Vaximm GmbH |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety and tolerability | Number of dose-limiting toxicities and maximum tolerated dose | 38 days | Yes |
Secondary | Immune response | Number of immune positive patients | Up to 24 months | No |
Secondary | Tumor staging | Tumor staging according to RECIST criteria | Up to 24 months | No |
Secondary | Tumor perfusion | Tumor perfusion determined by DCE-MRI | Up to 24 months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02495896 -
Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors
|
Phase 1 | |
Completed |
NCT02005315 -
A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer
|
Phase 1 | |
Completed |
NCT01453153 -
Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT01064622 -
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT00095966 -
Sorafenib and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
|
Phase 2 | |
Completed |
NCT02178436 -
Gemcitabine, Nab-paclitaxel and KPT-330 in Advanced Pancreatic Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT01846520 -
Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers
|
N/A | |
Completed |
NCT01647828 -
A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT01191684 -
Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic Cancer
|
Phase 1 | |
Terminated |
NCT01555489 -
Assessing the Efficacy and Safety of IV Vitamin C in Combination With Standard Chemotherapy for Pancreatic Ca
|
Phase 2 | |
Terminated |
NCT01233505 -
Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT01232829 -
Gamma Secretase Inhibitor RO4929097 in Previously Treated Metastatic Pancreas Cancer
|
Phase 2 | |
Completed |
NCT00735917 -
Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic Cancer
|
Phase 2 | |
Completed |
NCT02896907 -
Ascorbic Acid and Combination Chemotherapy in Treating Patients With Locally Advanced or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery
|
Early Phase 1 | |
Completed |
NCT02307539 -
Palliative Care in Improving Quality of Life in Patients With Newly Diagnosed Pancreatic Cancer
|
N/A | |
Completed |
NCT02050178 -
Dose Escalation Study of OMP-54F28 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer
|
Phase 1 | |
Completed |
NCT01488552 -
Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT01222689 -
Selumetinib and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
|
Phase 2 | |
Completed |
NCT00397787 -
Sunitinib in Treating Patients With Metastatic Pancreatic Cancer That Progressed After First-Line Therapy With Gemcitabine
|
Phase 2 | |
Completed |
NCT00028496 -
Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer
|
Phase 1 |